APATINIB-INDUCED HYPERTENSION ASSOCIATED WITH BETTER PROGNOSIS IN PATIENT WITH SOLID TUMOR

阿帕蒂尼 医学 内科学 单变量分析 癌症 入射(几何) 蛋白尿 肺癌 肿瘤科 胃肠病学 多元分析 物理 光学
作者
Caie Li,Liping Ma,Qiongying Wang,Xu Zhao,Ruixin Ma,Ningyin Li,Jing Yu
出处
期刊:Journal of Hypertension [Lippincott Williams & Wilkins]
卷期号:39 (Supplement 1): e153-e153
标识
DOI:10.1097/01.hjh.0000746056.15733.03
摘要

Objective: To investigate the incidence of apatinib-induced hypertension (HTN) in the treatment of patients with solid tumor in real world and to determine whether apatinib-induced HTN is associated with its anti-tumor efficacy. Design and method: We retrospectively collected the medical records of patients with solid tumor treated with apatinib in Lanzhou University Second Hospital and Gansu Provincial Cancer Hospital, from Oct 1st 2014 to Jun 30st 2019. The patients were then prospectively followed to determine the disease state, time of disease progression and death, as well as whether or not have newly initiated HTN. The mean follow-up was 16.5month, with the longest follow-up of 48 months. The apatinib-induced HTN was defined as either newly initiated HTN in patients with normal blood pressure or increases of antihypertensive intensity in patients with pre-existed HTN. The prognosis of patients was estimated with progression-free survival (PFS) and overall survival (OS). Results: A total of 400 patients were enrolled, of whom 136 (34%) were diagnosed with HTN induced by apatinib. The primary tumor in 40% of the patients were gastrointestinal cancer, followed by hepatobiliary cancer (14.5%) and lung cancer (13.3%). Patients in HTN group were older (p = 0.03), more frequently with proteinuria (p = 0.035) and higher dosage of apatinib (p = 0.024). The survival analysis showed that apatinib-induced HTN was associated with significantly longer PFS, as well as OS (both p < 0.01), the differences existed both in univariate and multivariate analyses. The subgroup analyses were performed in patients with gastrointestinal cancer, hepatobiliary cancer, and lung cancer, all showed consistent results. Conclusions: HTN is one of the most common side effects of apatinib in the treatment of solid tumors, with an incidence of as high as 34% in real world. Apatinib-induced HTN is significantly associated with better anti-tumor efficacy in patients with solid tumors. Given that there is still no effective predictive biomarker for apatinib, drug-induced HTN may be used as an surrogate one. The development of new antihypertensive drugs with better antihypertensive effects while no influences on antitumor activity, is in urgent need.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
妖妖灵发布了新的文献求助10
刚刚
13驳回了小二郎应助
1秒前
1秒前
wbh发布了新的文献求助10
2秒前
3秒前
4秒前
5秒前
佳里发布了新的文献求助10
7秒前
酸奶花生完成签到 ,获得积分10
7秒前
CT发布了新的文献求助10
8秒前
NexusExplorer应助11111采纳,获得10
9秒前
123完成签到,获得积分10
9秒前
13秒前
酷波er应助冷艳的姿采纳,获得10
14秒前
14秒前
小蘑菇应助缥缈冷安采纳,获得10
14秒前
ccygpp199发布了新的文献求助10
14秒前
NexusExplorer应助佳里采纳,获得10
15秒前
淡淡的向雁完成签到,获得积分10
15秒前
16秒前
16秒前
Jasper应助LJJ采纳,获得10
18秒前
小啦啦3082发布了新的文献求助10
18秒前
18秒前
19秒前
甜甜的悲完成签到,获得积分20
19秒前
今后应助wbh采纳,获得10
19秒前
20秒前
妖妖灵完成签到,获得积分20
20秒前
加油干发布了新的文献求助10
20秒前
彭于晏应助xuan采纳,获得10
20秒前
甜甜的悲发布了新的文献求助10
21秒前
gwenjing发布了新的文献求助10
22秒前
wsj发布了新的文献求助10
24秒前
24秒前
量子星尘发布了新的文献求助10
24秒前
张金蝶发布了新的文献求助10
24秒前
jinzhen发布了新的文献求助10
24秒前
文献发布了新的文献求助30
25秒前
太牛的GGB完成签到,获得积分20
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173